Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters

BMC Cancer

Volumn 17, Issue 1, 2017, Pages

  McDonnell, Alison M ^a,b   Cook, Alistair ^a,b   Robinson, Bruce W S ^a,b,c   Lake, Richard A ^a,b   Nowak, Anna K ^a,b,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Dendritic cells; Mesothelioma; Prognosis

Indexed keywords

CD40 ANTIGEN; CISPLATIN; CP 870893; HLA DR ANTIGEN; PEMETREXED; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CP-870,893; MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; BLOOD ANALYSIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; DENDRITIC CELL; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOLOGICAL MONITORING; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FEMALE; IMMUNOLOGY; IMMUNOMODULATION; LYMPHOCYTE COUNT; MALE; METABOLISM; NEOPLASM; PHASE 1 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROPORTIONAL HAZARDS MODEL; T LYMPHOCYTE SUBPOPULATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; CD40 ANTIGENS; CISPLATIN; CLINICAL TRIALS, PHASE I AS TOPIC; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOMODULATION; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; T-LYMPHOCYTE SUBSETS;

EID: 85027547510     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-017-3403-5     Document Type: Article

References (27)

1. Eliopoulos AG, Young LS. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004; 4(4): 360-367. 10.1016/j.coph.2004.02.008
2. Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 2013; 19(5): 1035-1043. 10.1158/1078-0432.CCR-12-20643590838
3. Khong A, Nelson DJ, Nowak AK, Lake RA, Robinson BW. The use of agonistic anti-CD40 therapy in treatments for cancer. Int Rev Immunol 2012; 31(4): 246-266. 10.3109/08830185.2012.698338
4. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, et al. Clinical activity and immune modulation in cancer patients treated with CP-870, 893, a novel CD40 agonist monoclonal antibody. J Clin Oncol Of. J Am Soc Clin Oncol. 2007;25(7):876-83
5. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003; 63(15): 4490-4496
6. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331(6024): 1612-1616. 10.1126/science.11984433406187
7. Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW, Hamid O. Phase I study of the CD40 agonist antibody CP-870, 893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology 2013; 2(1. 10.4161/onci.230333583942
8. Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH. A phase I study of an agonist CD40 monoclonal antibody (CP-870, 893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res 2013; 19(22): 6286-6295. 10.1158/1078-0432.CCR-13-1320
9. Nowak AK, Cook AM, McDonnell A, Millward M, Creaney J, Francis RJ, Hasani A, Segal A, Musk AW, Turlach BA et al: A phase 1b clinical trial of the CD40 activating antibody CP-870, 893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Ann Oncol 2015 (in press)
10. Ruter J, Antonia SJ, Burris HA, Huhn RD, Vonderheide RH. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther 2010; 10(10): 983-993. 10.4161/cbt.10.10.132513047092
11. Hunter TB, Alsarraj M, Gladue RP, Bedian V, Antonia SJ. An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model. Scand J Immunol 2007; 65(5): 479-486. 10.1111/j.1365-3083.2007.01927.x
12. Byrne MJ. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 2004; 15(2): 257-260. 10.1093/annonc/mdh059
13. Francis RJ, Byrne MJ, Schaaf AA, Boucek JA, Phillips M, Price R, Patrikeos AP, Musk AW, Millward MJ. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 2007; 48(9): 1449-1458. 10.2967/jnumed.107.042333
14. Cook AM, McDonnell AM, Lake RA, Nowak AK. Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. Oncoimmunology 2016; 5(3): e1066062. 10.1080/2162402X.2015.1066062
15. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol (Baltimore, Md: 1950) 1984; 133(4): 1710-1715
16. Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol 2003; 3(12): 939-951. 10.1038/nri1248
17. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, Kroczek RA. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999; 397(6716): 263-266. 10.1038/16717
18. McCoy MJ, Nowak AK, Most RG, Dick IM, Lake RA. Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies. Cancer immunol, immunother: CII 2012; 62(3): 529-539. 10.1007/s00262-012-1360-z
19. Miller JD, Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008; 28(5): 710-722. 10.1016/j.immuni.2008.02.020
20. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GMA, Papagno L, Ogg GS, King A, Lechner F, Spina CA. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002; 8(4): 379-385. 10.1038/nm0402-379
21. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Klenerman P, Walker BD. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191(9): 1499-1512. 10.1084/jem.191.9.14992213430
22. Callan MF, Tan L, Annels N, Ogg GS, Wilson JD, O'Callaghan CA, Steven N, McMichael AJ, Rickinson AB. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med 1998; 187(9): 1395-1402. 10.1084/jem.187.9.13952212279
23. Hildeman DA, Zhu Y, Mitchell TC, Bouillet P, Strasser A, Kappler J, Marrack P. Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim. Immunity 2002; 16(6): 759-767. 10.1016/S1074-7613(02)00322-9
24. Carpenter EL, Mick R, Ruter J, Vonderheide RH. Activation of human B cells by the agonist CD40 antibody CP-870, 893 and augmentation with simultaneous toll-like receptor 9 stimulation. J Transl Med 2009; 7: 93. 10.1186/1479-5876-7-932777861
25. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 2007; 13(4): 1083-1088. 10.1158/1078-0432.CCR-06-1893
26. Boltjes A, Van Wijk F. Human dendritic cell functional specialization in steady-state and inflammation. Front Immunol. 2014;5:131
27. Collin M, McGovern N, Haniffa M. Human dendritic cell subsets. Immunology. 2013;140(1):22-30